Ocata Therapeutics Inc fka OCAT

[rocky301]

Dianne,

Any reason why RPE's would be ineffective with "wet" AMD?
Do we know why ACTC is working with "dry" versus "wet"?

Wet AMD is neovascular where unwanted blood vessels form causing damage. Stargardts and dry AMD are non-neovascular and do have similarities. Simply put, the years performing animal studies and preparing for the IND were geared to produce results towards Stargardts and dry AMD. As noted from a link 3 years ago ACT knew what they were shooting for. Dry AMD represents 90% of AMD market and Stargardts was chosen for Orphan benefits and early results. Both will be subretinal injections and appear to be complimentary in some forms to the end result. These are just a FEW points as to the why.

February 01 2008
" ACT is working with the agency to fulfill the FDA's requirements to bring its RPE cell therapy into human clinical trials for the treatment of retinal degenerative diseases such as Retinitis Pigmentosa, Stargardt's disease, and dry age-related macular degeneration (AMD)."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=26460090